KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EBITDA: 2009-2024

Historic EBITDA for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Dec 2024 value amounting to -$232.9 million.

  • Vertex Pharmaceuticals' EBITDA rose 6.26% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year increase of 1576.85%. This contributed to the annual value of -$232.9 million for FY2024, which is 106.08% down from last year.
  • According to the latest figures from FY2024, Vertex Pharmaceuticals' EBITDA is -$232.9 million, which was down 106.08% from $3.8 billion recorded in FY2023.
  • Over the past 5 years, Vertex Pharmaceuticals' EBITDA peaked at $4.3 billion during FY2022, and registered a low of -$232.9 million during FY2024.
  • For the 3-year period, Vertex Pharmaceuticals' EBITDA averaged around $2.6 billion, with its median value being $3.8 billion (2023).
  • In the last 5 years, Vertex Pharmaceuticals' EBITDA skyrocketed by 138.52% in 2020 and then slumped by 106.08% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' EBITDA (Yearly) stood at $2.9 billion in 2020, then fell by 2.60% to $2.8 billion in 2021, then skyrocketed by 54.83% to $4.3 billion in 2022, then fell by 11.04% to $3.8 billion in 2023, then tumbled by 106.08% to -$232.9 million in 2024.